技术指标
指标
数值
方向
MACD(12,26,9)
-0.097
中性
RSI(14)
57.474
中性
STOCH(KDJ)(9,3,3)
38.354
中性
ATR(14)
0.504
低波动
CCI(14)
11.664
中性
Williams %R
62.238
卖出
TRIX(12,20)
0.414
卖出
StochRSI(14)
71.925
买入
搜索
ImmuCell Corp
ICCC添加自选
11.210USD
+0.150+1.36%
收盘 07-31 16:00（美东）报价延迟15分钟
101.40M总市值
亏损市盈率 TTM
关键数据
10.980今开
11.350最高
10.15K成交量
亏损市盈率 TTM
--市盈率动
--股息TTM
0.11%换手率
11.060昨收
10.970最低
76.44K成交额
亏损市盈率静
3.75市净率
0.00%股息率 TTM
-1.22%ROA
10.75052周最高
0.60量比
-2.16M净利润
9.05M总股本
-0.0617每股收益TTM
0.54Beta
-1.88%ROE
4.52052周最低
3.44%振幅
44.97%毛利率
101.40M总市值
3.26回报/风险
3.05%风险率
TradingKey ImmuCell Corp股票评分
单位: USD 更新时间: 2026-07-31操作建议
ImmuCell Corp当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名113/155位。机构持股占比非常高，中期看，股价处于上升通道。近一个月，市场表现较强，基本面评分较高，但较强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
ImmuCell Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
ImmuCell Corp亮点
亮点风险
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
业绩高增长
公司营业收入稳步增长，连续3年增长58.22%
业绩增长期
公司处于发展阶段，最新年度总收入27.64M美元
估值低估
公司最新PE估值-181.69，处于3年历史低位
机构加仓
最新机构持股2.16M股，环比增加9.59%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值0.00
分析师目标
根据
0
位分析师
--
评级
--
目标均价
--
涨幅空间
ImmuCell Corp新闻
即将为您带来更多新闻，敬请期待。。。
技术指标
移动平均线
指标
数值
方向
MA5
11.130
买入
MA10
11.108
买入
MA20
11.012
买入
MA50
10.344
买入
MA100
8.912
买入
MA200
7.488
买入
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
ImmuCell Corp简介
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
公司代码ICCC
公司ImmuCell Corp
CEOte Boekhorst (Olivier)
网址https://immucell.com/
公司股东
相关品种
热门品种
常见问题
ImmuCell Corp(ICCC)的当前股价是多少？
ImmuCell Corp(ICCC)的当前股价是 11.21。
ImmuCell Corp的股票代码是什么？
ImmuCell Corp的股票代码是ICCC。
ImmuCell Corp股票的52周最高点是多少？
ImmuCell Corp股票的52周最高点是10.75。
ImmuCell Corp股票的52周最低点是多少？
ImmuCell Corp股票的52周最低点是4.52。
ImmuCell Corp的市值是多少？
ImmuCell Corp的市值是101.40M。
ImmuCell Corp(ICCC)股票的每股收益（EPS TTM）是多少
ImmuCell Corp(ICCC)股票的每股收益（EPS TTM）是-0.12。